Miraqules co-founder and CEO Sabir Hossain all the time knew he wished to comply with in his father’s footsteps and run his personal enterprise. However he by no means thought he’d launch a biotech firm constructed round a expertise that might have been capable of assist his father after a near-tragic accident years earlier left him nearly bleeding to loss of life.
Bengaluru-based Miraqules developed a nanotechnology in powder kind that mimics blood clotting proteins. The blood clotting powder quickly produces fibrous compounds at room temperature which might be a excessive quantity to ratio and may take in blood rapidly when utilized.
“This is a product that will give you feedback instantly,” Hossain informed TechCrunch. “If there is a person bleeding, you apply it, and the bleeding stops. This whole thing happens within one or two minutes.”
Miraqules is a Prime 20 Startup Battlefield finalist and will probably be presenting this expertise on stage at TechCrunch Disrupt 2025, this week in San Francisco.
Hossain stated he developed the expertise nearly by chance.
He went to grad faculty for biomedical engineering and began working in a analysis lab targeted on biomaterials the place his job was basically to imitate the work of a doctorate pupil.
“I was really bad at that, actually,” Hossain stated. “Her job was to create 3D structures that will help in bone tissue growth, that could help in bone generation. Every time I was synthesizing that material, it was getting dismantled.”
Techcrunch occasion
San Francisco
|
October 27-29, 2025
At some point he took the dismantled particles and floor it right into a powder. He introduced this powder to a gaggle engaged on blood clotting that was struggling to combine their resolution correctly to see if it may assist — and it labored.
“It clotted the whole blood within maybe five to 10 seconds. I rushed to my professor and then from there we started to think about what made it happen,” Hossain stated. “We came up with the completely new process of combining off-the-shelf materials into a nanomaterial that mimics blood clotting proteins.”
Hossain then paired up together with his childhood good friend, Mubeen Midda, they usually began making an attempt to develop the expertise so it could possibly be taken out of the lab — with as little funding as potential.
Since then, the corporate has been capable of safe 11 patents throughout seven completely different nations, together with India, the USA, and Israel.
Miraqules’ tech is already being piloted in a trauma care heart in India, and the corporate expects to get its regulatory clearance in India throughout the subsequent few months. It is also on observe to obtain clearance from the U.S. Meals and Drug Administration in 2026.
“One thing we did from the beginning, we directly went to the U.S. FDA, there is something called pre-submission. We tried to get their feedback on what other necessary things that we need to do to get this product approved, that helped us a lot.”
The corporate has reached these milestones with lower than $700,000 in capital raised, largely from grants.
Miraqules is seeking to ramp up deployment and pilot applications heading into subsequent yr. It has already obtained potential curiosity from 10 completely different hospital chains in India and the Israeli Protection Forces.
If you wish to be taught from Miraqules firsthand, and see dozens of extra pitches, attend worthwhile workshops, and make the connections that drive enterprise outcomes, head right here to be taught extra about this yr’s Disrupt, held October 27 to 29 in San Francisco.
